By innovatively modulating the expression of CX3C chemokine receptor 1 (CX3CR1) and IL-25, researchers have enhanced the immunosuppressive potential of MSCs for a more effective treatment of IBD [28]. This evidence concerns the gene CX3CR1 and inflammatory bowel disease.